Tetraphase Pharmaceuticals Inc. (TTPH)

0.42
NASDAQ : Health Technology
Prev Close 0.43
Day Low/High 0.41 / 0.46
52 Wk Low/High 0.41 / 3.74
Avg Volume 596.40K
Exchange NASDAQ
Shares Outstanding 54.26M
Market Cap 23.33M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today...

Is antibiotic-resistant bacteria a curse or a blessing for Big Pharma?

Is antibiotic-resistant bacteria a curse or a blessing for Big Pharma?

By Ben Levine for Kapitall. At the end of April, the World Health Organization (WHO) for the first time ever [...]

Tetraphase Pharmaceuticals Inc Stock Upgraded (TTPH)

Tetraphase Pharmaceuticals Inc Stock Upgraded (TTPH)

Tetraphase Pharmaceuticals (Nasdaq:TTPH) has been upgraded by TheStreet Ratings from a sell to hold.

Ratings Changes Today

Upgrades: CTCM, NAT, TTPH, UAM, XOXO Downgrades: ISLE, PRPH, WIFI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Tetraphase Pharmaceuticals Completes Enrollment In Lead-in Portion Of IGNITE 2 Eravacycline Phase 3 Clinical Trial In CUTI

Tetraphase Pharmaceuticals Completes Enrollment In Lead-in Portion Of IGNITE 2 Eravacycline Phase 3 Clinical Trial In CUTI

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced today that it has completed patient enrollment in the lead-in portion of its IGNITE 2 clinical trial.

Tetraphase Pharmaceuticals Adds Dr. Jeffrey Chodakewitz To Board Of Directors

Tetraphase Pharmaceuticals Adds Dr. Jeffrey Chodakewitz To Board Of Directors

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today...

Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today...

Ratings Changes Today

Upgrades: EEP, IIN, INN, IOC, NMFC, SPWR, UEPS Downgrades: ADSK, AMS, BDGE, BTG, CHLN, FFBC, IRDM, ITI, SGMS, VIPS Initiations: TTPH Read on to get TheStreet Quant Ratings' detailed report:

Tetraphase Pharmaceuticals To Present At The Annual UBS Global Healthcare Conference

Tetraphase Pharmaceuticals To Present At The Annual UBS Global Healthcare Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today...

Tetraphase Pharmaceuticals Reports First-Quarter 2014 Financial Results

Tetraphase Pharmaceuticals Reports First-Quarter 2014 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant (MDR) bacteria,...

Tetraphase To Present Data On Advancing Product Pipeline At 24th ECCMID

Tetraphase To Present Data On Advancing Product Pipeline At 24th ECCMID

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the upcoming presentation of six scientific posters at the 24 th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) taking...

Emerging 'Superbugs' -- and Why Investors Should Care

Emerging 'Superbugs' -- and Why Investors Should Care

Antibiotic-resistant 'superbugs' are spreading, and drug companies and their investors should take notice.

FDA Awards Fast Track Status To Tetraphase Pharmaceuticals For IV And Oral Formulations Of Eravacycline

FDA Awards Fast Track Status To Tetraphase Pharmaceuticals For IV And Oral Formulations Of Eravacycline

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the U.

Tetraphase Antibiotic Nearing Key Tolerability Test

Tetraphase Antibiotic Nearing Key Tolerability Test

The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.

Tetraphase Pharmaceuticals Becomes Oversold (TTPH)

Tetraphase Pharmaceuticals Becomes Oversold (TTPH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Tetraphase Pharmaceuticals To Present At Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against drug-resistant bacteria, today...

Tetraphase Pharmaceuticals Provides Update On Clinical Progress Of Phase 3 Lead Antibiotic Candidate Eravacycline

Tetraphase Pharmaceuticals Provides Update On Clinical Progress Of Phase 3 Lead Antibiotic Candidate Eravacycline

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today provided a clinical update on its lead antibiotic candidate, eravacycline, and its Phase 3 global clinical program IGNITE ( Investigating Gram- negative ...

Tetraphase Pharmaceuticals Adds Nancy J. Wysenski To Board Of Directors

Tetraphase Pharmaceuticals Adds Nancy J. Wysenski To Board Of Directors

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today...

Tetraphase Reports Fourth-Quarter And Full-Year 2013 Financial Results

Tetraphase Reports Fourth-Quarter And Full-Year 2013 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.

Tetraphase Pharmaceuticals To Present At Upcoming Investor Conferences

Tetraphase Pharmaceuticals To Present At Upcoming Investor Conferences

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria,...

Tetraphase Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference

Tetraphase Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria...

Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer

Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the appointment of Craig Thompson to the position of Chief Operating Officer, effective immediately.

Tetraphase Pharmaceuticals Announces Exercise Of Underwriters’ Option To Purchase Additional Shares In Follow-On Offering

Tetraphase Pharmaceuticals Announces Exercise Of Underwriters’ Option To Purchase Additional Shares In Follow-On Offering

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the underwriters for its recent follow-on offering have exercised their option to purchase additional shares and purchased an additional 407,403 ...

Tetraphase Reports Third-Quarter 2013 Financial Results

Tetraphase Reports Third-Quarter 2013 Financial Results

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter ended September 30, 2013.

Tetraphase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of an underwritten public offering of 4.

Tetraphase Pharmaceuticals Announces Proposed Offering Of Common Stock

Tetraphase Pharmaceuticals Announces Proposed Offering Of Common Stock

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced it has commenced an underwritten public offering of 3,300,000 shares of its common stock.

3 Antibiotic Stocks Targeting Most Urgent Bacterial Threats

3 Antibiotic Stocks Targeting Most Urgent Bacterial Threats

Cubist, Cempra and Tetraphase are all developing antibiotics to combat a new wave of scary bacterial superbugs.

Tetraphase To Present New Data At IDWeek On Eravacycline’s Potential Activity In Treating Serious Respiratory Infections

Tetraphase To Present New Data At IDWeek On Eravacycline’s Potential Activity In Treating Serious Respiratory Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that it will present two posters at IDWeek 2013 that examine the potential of its lead antibiotic candidate, eravacycline, to treat serious...

Tetraphase Outlines Plans For Phase 3 Clinical Trial Of Eravacycline IV/oral In Complicated Urinary Tract Infections

Tetraphase Outlines Plans For Phase 3 Clinical Trial Of Eravacycline IV/oral In Complicated Urinary Tract Infections

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), today announced the design of its planned Phase 3 IV/oral clinical trial of the Company’s lead antibiotic candidate eravacycline in the treatment of complicated ...

4 Biotech Stocks Triggering Breakout Trades

4 Biotech Stocks Triggering Breakout Trades

Keep thees biotech stocks trading on unusual volume on your radar.

TheStreet Quant Rating: D (Sell)